ALX-0171 had an immediate and significant impact on viral replication and an encouraging initial therapeutic effect in a Phase IIa study in hospitalised infants with a RSV infection [1] GHENT, Belgium ...

GHENT, Belgium, 30 April 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that it has successfully completed patient recruitment in the Phase IIb RESPIRE dose-ranging efficacy study ...

GHENT, Belgium, 2 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that the first patient has been dosed in the Japanese Phase II study of ALX-0171, the Company's wholly-owned ...

Atriva Therapeutics announces publication of results from the Phase 2a RESPIRE study in eClinicalMedicine (part of THE LANCET Discovery Science) Results reflect clinically relevant efficacy for ...

Jan 11 (Reuters) - Ablynx NV : * Ablynx initiates the phase IIB "respire" study of its wholly-owned, first-in-class, inhaled anti-rsv nanobody, ALX-0171, for the treatment of RSV infections in ...

REGULATED INFORMATION - INSIDE INFORMATION GHENT, Belgium, 30 April 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that it has successfully completed patient recruitment in the ...